Microsoft Corporation has made a move into genetic data management, following its acquisition of Rosetta Inpharmatics LLC, a subsidiary of pharmaceutical firm Merck & Co.
The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft’s recently announced Amalga Life Sciences effort.
The agreement calls for Microsoft and Merck to collaborate on software to improve drug discovery and development. Financial details were not disclosed.
Link